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Abstract Hepatocyte growth factor/scatter factor (HGF/SF)
and macrophage stimulating protein (MSP) are plasminogen-
related kringle proteins that lost serine protease domain
enzymatic activity and became ligands for cell surface tyrosine
kinase receptors. They are activated by cleavage to disulfide-
linked KL chains. Surprisingly, despite structural similarities, the
high affinity receptor binding regions of the two proteins are
different: K chain for HGF, and L chain for MSP. We propose
that after cleavage exposes a L chain binding site (high affinity
for MSP, low affinity for HGF), monomeric ligand induces
receptor dimerization and activation via K and L chain binding
sites of different affinity.
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1. Introduction
Met [1] and Ron [2,3] genes encode cell membrane receptor
protein tyrosine kinases, that mediate cell proliferation or
motility in several tissues. Their activating ligands, hepatocyte
growth factor/scatter factor (HGF/SF) and macrophage stim-
ulating growth factor (MSP) respectively, comprise a distinct
family of growth factors that evolved from plasminogen [4].
HGF promotes growth, di¡erentiation and migration of a
wide variety of cells, including epithelia of numerous organs,
vascular endothelium, neurons, myogenic precursor cells, os-
teoblasts and osteoclasts (for a review see [5]). Activating
mutations of Met have recently been shown to occur in se-
lected cases of renal papillary carcinoma [6], and there is
evidence for autocrine HGF-Met signaling in various human
carcinomas and sarcomas. Uncontrolled activation of Met is
associated with tumor invasion and metastasis in several ex-
perimental models (for a review, see [7]). There is great inter-
est in the possible therapeutic potential of HGF for tissue
regeneration [5] and of HGF-Met antagonists for a broad
spectrum of human malignancies. Targets for MSP include
keratinocytes [8,9], subpopulations of macrophages [10], and
selected cells of the hematopoietic system [11,12]. Although it
is closely related to HGF-Met in structure and function,
MSP-Ron has not yet been shown to have a role in tumori-
genesis.
HGF and MSP have 45% sequence homology to each oth-
er, and 40% to plasminogen. They have the same domain
organization: N-terminal domain (N domain) containing a
hairpin loop motif, four kringles, a cleavage site for activating
the protein, and a serine protease-like (sp) domain. They are
secreted as single chain precursors, which are converted to
mature proteins by cleavage at a single site to make a disul-
¢de-linked KL chain heterodimer [13,14]. The K chain contains
the N domain and the kringles; the L chain comprises the
serine protease (sp) domain, which is devoid of enzymatic
activity due to catalytic triad mutations.
The receptor subfamily comprises Met, Ron and Sea [15].
Each receptor is composed of two disul¢de linked subunits:
an extracellular K chain and a L chain containing extracellu-
lar, transmembrane and intracellular regions. The domain
with tyrosine kinase activity is located within the intracellular
part of the L chain. Other unique structural features of this
family include similar location of cysteine residues in the ex-
tracellular domain and two conserved tyrosines in the car-
boxy-terminal tail.
2. How do HGF and MSP activate their speci¢c receptors?
2.1. The primary receptor binding site of HGF is located
within the N-terminal region NK1
Studies of HGF receptor binding and biological responses
[16,17] have established the following: (i) single-chain pro-
HGF binds to Met, though a⁄nity is lower than that of
cleaved, biologically active KL chain HGF; (ii) a fragment
comprising the N-terminal 272 residues of HGF binds to
Met with a Kd 4-fold higher than that of HGF; an HGF
variant lacking the N-domain does not bind to Met; (iii)
only full length, unmodi¢ed HGF can induce an optimal
downstream biological response.
Studies of two HGF variants provided additional data on
binding to Met. One variant, called HGF-NK2, is derived
from an alternative transcript, and comprises the N-terminus
and the ¢rst two kringles [18]. HGF-NK2 binds to Met with
high a⁄nity, and inhibits binding and activity of wild-type
HGF. The role of the N domain in binding was studied
with another HGF isoform, NK1. The hairpin loop is char-
acterized by a high density of positively charged residues.
Substitution of two positively charged residues in the loop
with alanine markedly reduced biological potency [19,20].
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2.2. The primary receptor binding site of MSP is located
in the L-chain
A structure-activity study using pro-MSP, MSP, K chain, L
chain, and an MSP-NK2 variant, revealed that only MSP was
biologically active; the L chain was a weak MSP antagonist
[21]. In contrast to HGF, free MSP L chain binds with high
a⁄nity to its receptor (Kd 1.4 nM for L chain, Kd 0.6^0.8 nM
for MSP), whereas a binding site on the K chain is undetect-
able, as shown by no binding of pro-MSP or MSP-NK2.
Absence of pro-MSP binding to Ron shows that the L chain
binding site is exposed only after proteolytic cleavage to the
MSP heterodimer. Modeling studies (based on an HGF L
chain three-dimensional model [4]), revealed that Arg-639,
641, 683, 687, and 689 form a cluster of positively charged
residues on the MSP sp domain surface (Fig. 1), which may
account for its high a⁄nity binding to Ron.
2.3. Hypothetical mechanism of receptor dimerization and
activation
It has been generally accepted [22] that ligand-induced re-
ceptor activation involves dimerization of receptors followed
by autophosphorylation occurring in trans (between two mol-
ecules) of speci¢c tyrosines in the cytoplasmic portion of the L
chain. Phosphorylation of conserved tyrosine residues within
the active site of the tyrosine kinase domain upregulates the
kinase activity of the receptor; the phosphorylated carboxy-
terminus is a docking site for several SH2 containing proteins
[23]. How do MSP and HGF induce dimerization of their
receptors? Two di¡erent experimentally veri¢ed models of re-
ceptor dimerization by growth factors are relevant. In the case
of the binding of stem cell factor (SCF) to its receptor, Kit,
SCF dimers bind to pairs of Kit receptors, the stoichiometry
being 2:2 [24,25]. In the human growth hormone (HGH)
model, the stoichiometry is 1:2: one region of an HGH
monomer binds with high a⁄nity to its receptor (R1), after
which another region of HGH binds to a second receptor
(R2). Although the second site binding a⁄nity is lower, the
complex is stabilized by an R1/R2 interaction as the receptors
are brought into proximity by HGH [26,27]. Several observa-
tions lead us to favor the HGH model for ligand-induced
dimerization of Met and Ron (Fig. 2A).
(1) Sequence and domain structure of MSP/Ron and HGF/
Met signaling systems are very similar. These include the N
domain, which is homologous to the plasminogen preactiva-
tion peptide, and is retained in the mature form of both li-
gands. The evolution of MSP and HGF from plasminogen
suggests that the same domains would be utilized by both
growth factors for interaction with their receptors. (2)
Although the ligand-receptor interface is usually complex
and extensive, only a few residues account for most of the
binding free energy [28]. It is likely that positively charged
residues are critical for binding to Met or Ron, clusters of
which are located in the K chain of HGF [4] and in the L
chain of MSP (Fig. 1). Thus, despite their structural similar-
ity, the regions of MSP and HGF that bind with high a⁄nity
to their receptors are di¡erent. For HGF, it is the K chain
(speci¢cally, the N domain of the K chain); for MSP, it is the
L chain. (3) Interaction of ligand with receptor via the high
a⁄nity binding site is insu⁄cient to activate the receptor; a
second region of the ligand is required. For HGF, this second
site is cryptic, and becomes exposed after speci¢c cleavage of
pro-HGF to the disul¢de-linked KL chain heterodimer. Thus,
non-cleavable pro-HGF mutants bind to soluble Met, but
have no biological activity on hepatocyte target cells [16].
Since HGF and MSP evolved from zymogens, the serine pro-
tease L chains of which become active after KL chain cleavage,
it is likely that proteolytic cleavage of pro-HGF to biologi-
cally active HGF results in exposure of a second binding site
that is located in the L chain. This idea is supported by the
fact that HGF mutants without L chain bind but do not
activate [16]. (4) MSP binding is the converse of HGF. The
high a⁄nity binding site is hidden in the L chain of pro-MSP,
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Fig. 1. Distinct features in the MSP L chain, which are not present
in the corresponding region of HGF, that may account for receptor
binding (based on comparison of 3D models [4]). (1) Cluster of ar-
ginines. (2) Conformation of Arg-683, 687 and 689 is stabilized by
hydrophobic interactions between alkyl portions of their side chains
and the indole ring of Trp-690. (3) Glu-648 and Asn-682 are buried
in the region corresponding to the substrate binding pocket in tryp-
sin. (4) Backbone tracing of the exposed hydrophobic loop (green)
comprises sequence Leu-650, Leu-651, Ala-652, Pro-653 and Val-
654.
Fig. 2. Two models of receptor dimerization. A: Dimerization of
Met or Ron with a ligand:receptor stoichiometry of 1:2. B: Dimeri-
zation of Met by a heparin-NK1 complex, with an NK1:Met stoi-
chiometry of 2:2.
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and becomes exposed by proteolytic cleavage to MSP. This
accounts for the fact that ^ in contrast to pro-HGF, which
has its high a⁄nity binding site in the K chain ^ pro-MSP
does not bind to receptor. Although free L chain binds with
high a⁄nity to Ron, it does not induce biological activity or
receptor phosphorylation. Requirement for the whole mole-
cule suggests that there is a second receptor binding site in the
MSP K chain. This possibility is currently being evaluated. (5)
The Kd values of HGF or MSP variants that bind to receptor
(HGF-NK1, HGF-NK2, pro-HGF, MSP L chain) are 2^10-
fold higher than the Kds of the mature intact ligands. This is
consistent with the suggestion that the mature ligands have
two binding sites for their receptors.
Is the experimental evidence consistent with the alternative
model of receptor dimerization induced by a ligand dimer?
Neither MSP nor HGF are dimers in solution at physiological
concentrations. Heparin-like oligosaccharides can induce di-
merization of HGF [29], and therefore dimer formation might
be induced by cell surface proteoglycan. HGF-NK1 did not
bind to glycosaminoglycan-de¢cient CHO-745 cells, but could
bind and cause Met tyrosine phosphorylation in the presence
of added heparin [20]. In view of this proteoglycan-dependent
agonist activity, it is possible to imagine a proteoglycan-linked
NK1 dimer that binds to a pair of Met receptors via the NK1
high a⁄nity sites (Fig. 2B and [30]). However, this model may
have no relationship to how full-length HGF induces receptor
dimerization, for which mature HGF L-chain is a require-
ment. Furthermore several lines of evidence show that sul-
fated polysaccharides are not required for HGF/Met interac-
tion. HGF binds to soluble Met receptor in the absence of
heparan sulfate, and it induces biological activity in cell line
mutants that do not express heparan sulfate ([30], pp. 150^
153). If the reason that both chains are required for receptor
activation is formation of ligand dimers, this would involve
binding of HGF to Met via K chains and interaction of a pair
of HGF molecules via their L chains [30]. For MSP, binding
to Ron would be via L chains, with dimer formation via K
chain pairing. This requires postulating two di¡erent sets of
intermolecular interaction sites (L chains for HGF and K
chains for MSP), which cannot be ruled out, but are unknown
at present. In contrast, the 1 ligand:2 receptor model involves
ligand/receptor interaction regions that are already known,
and a common mechanism for pro-MSP and pro-HGF acti-
vation by cleavage that exposes a L chain receptor binding
site. In analogy to the HGH model, HGF K chain binds to
Met receptor 1, after which HGF L chain can bind to Met
receptor 2 (Fig. 2A). The converse is the case for MSP and
Ron. It is assumed that the ligand/receptor interfaces for these
two growth factors are similar, the di¡erences in a⁄nities of
their corresponding chains being accounted for by a small
number of surface residues. The complex is presumably stabi-
lized by interactions between receptor pairs. When soluble
recombinant receptor becomes available, it may be possible
to determine ligand:receptor stoichiometry and also to test
our hypothesis that HGF and MSP ligands are bivalent
with respect to receptor binding.
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